Poh, C., Hernandez-Ilizaliturri, F., Trneny, M., Wu, J., Colucci, P., Bortolami, O., Sehn, L. (2025). Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age. Blood. https://doi.org/10.1182/blood-2025-3582